


Do you have Becker Muscular Dystrophy? Are you interested in participating in a clinical trial?

Join the OCANYON Trial.

The Canyon Trial

Edgewise Therapeutics is seeking individuals living with BMD for the phase 2 trial of EDG-5506, an investigational treatment for BMD. The Canyon trial aims to evaluate the effect of EDG-5506 on safety, tolerability, biomarkers of muscle damage and functional measures in individuals living with BMD. Participation is approximately 14 months and requires up to 10 site visits during the trial.



The Investigational Therapy

EDG-5506 is designed to reduce the skeletal muscle stress and injury that occurs in individuals with BMD. EDG-5506 aims to prevent skeletal muscle breakdown, inflammation, and the functional decline that accompany disease progression in BMD.

Who Can Participate?

Approximately 48 adults and 18 adolescents living with BMD are expected to be enrolled at sites across the United States, United Kingdom, and the Netherlands.

- Genetic diagnosis of Becker Muscular Dystrophy
- Male, ages 12 50 years
- Ability to complete physical function activities (i.e., North Star Ambulatory Assessment, 100-meter timed test)
- Able to meet other criteria as specified

Travel and other resources will be coordinated and provided for eligible participants.

Sites across the United States, United Kingdom, and the Netherlands are enrolling for the CANYON trial. For more information, please go to clinicaltrials.gov (NCT05291091) or contact studies@edgewisetx.com.





